Sarah Thuerk
Sarah Thuerk is associate editor of Healthcare Traveler magazine.
AADA dissatisfied with SGR patch
The Senate passed another one-year fix to the sustainable growth rate (SGR) formula, to the dismay of the American Academy of Dermatology Association and numerous other physician advocate groups.
FDA approves oral drug for psoriatic arthritis
The Food and Drug Administration has approved an oral medication, Otezla (apremilast, Celgene) for the treatment of adult patients with active psoriatic arthritis.
High-dose vitamin D may alleviate urticaria
High-dose vitamin D3 as an adjuvant therapy holds potential benefit for patients suffering from chronic urticaria, according to results of a recent study.
Researchers ID underlying cause of atopic dermatitis
Researchers ID underlying cause of atopic dermatitis
Staphylococci bacteria on the skin’s surface can produce a biofilm that occludes the sweat ducts, which results in atopic dermatitis and eczema, according to results of a recent study.
Emphasis on aging prompts sunscreen use in teens
Using educational videos focused on premature aging caused by sun exposure was more likely to improve teens’ sunscreen use than videos focused on skin cancer risk, a recent study suggests.
PhotoMedex to acquire LASIK provider
The skincare company PhotoMedex has signed a definitive agreement to acquire LASIK provider LCA-Vision for more than $106 million.
Congress agrees to repeal sustainable growth rate formula
Members of Congress have reached an agreement that would repeal the sustainable growth rate formula, which is used to determine Medicare reimbursement rates for physicians. The agreement allows for guaranteed annual reimbursement increases of 0.5 percent over the next five years for Medicare providers.
Valeant to acquire PreCision Dermatology for $475M
Valeant Pharmaceuticals International has entered into a definitive agreement to acquire PreCision Dermatology for $475 million in cash plus $25 million payable upon achievement of a sales milestone.
FDA approves Xolair for chronic idiopathic urticaria
The Food and Drug Administration has approved Xolair (omalizumab, Novartis) for the treatment of chronic idiopathic urticaria in patients ages 12 and older.
Travel deals for travel nurses
Travel nurses find cheap flights, low-cost lodging, deals on wheels, and budget entertainment and getaways.

Poll

View Results